Market Place
Sourcing Support
Inversago was working toward a potential 2024 IPO
22 Aug 2023 //
ENDPTS
Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion
11 Aug 2023 //
CNBC
Inversago Pharma Presents Data from Phase 1b Trial of INV-202
23 Jun 2023 //
BUSINESSWIRE
Inversago Pharma to Present Data from Phase 1b Trial of INV-202
08 Jun 2023 //
BUSINESSWIRE
Inversago Pharma Announces New Data to be Presented at the 2023 Conference
22 May 2023 //
BUSINESSWIRE
Inversago to Participate at the 2023 SVB Securities Global Biopharma Conference
24 Jan 2023 //
BUSINESSWIRE
Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202
29 Nov 2022 //
BUSINESSWIRE
Inversago Appoints Ed Mathers and Nanna Lüneborg to its Board of Directors
19 Oct 2022 //
BUSINESSWIRE
Inversago Appoints of Ed Mathers & Nanna Lüneborg to Board of Directors
19 Oct 2022 //
BUSINESSWIRE
Inversago Pharma Raises $95 million CAD in Series C Financing
17 Oct 2022 //
BUSINESSWIRE
Inversago Pharma receives IND clearance for Phase 2 trial of INV-202
15 Sep 2022 //
BUSINESSWIRE
Inversago Pharma Presents Data on INV-202 in Diabetic Nephropathy
19 May 2022 //
BUSINESSWIRE
Inversago Pharma Appoints Glenn S. Vraniak as Chief Financial Officer
16 May 2022 //
BUSINESSWIRE
Inversago Pharma to Present at Upcoming Bloom Burton & Co. Conference
11 Apr 2022 //
BUSINESSWIRE
Inversago Pharma says Dosing of First Participant With Metabolic Syndrome
15 Mar 2022 //
BUSINESSWIRE
Inversago Pharma Completes Phase 1 Clinical Trial on Peripheral CB1 Blocker
17 Jan 2022 //
BUSINESSWIRE
Inversago Pharma begins a phase 1 clinical trial with INV-202
09 Sep 2021 //
BUSINESSWIRE
Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202
07 Sep 2021 //
BUSINESSWIRE
Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202
07 Sep 2021 //
FINANCIALPOST
Inversago Pharma Receives Rare Pediatric Disease from the FDA for INV-101
07 Jan 2021 //
BUSINESSWIRE
Inversago Pharma Receives Rare Pediatric Disease Designation from the FDA
07 Jan 2021 //
BUSINESSWIRE
Inversago Pharma Continues to Rapidly Expand Its Leadership Team
30 Nov 2020 //
BUSINESSWIRE
Inversago Pharma Initiates Clinical Trials, with a Phase 1 study of INV-101
29 Sep 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.